3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
3
Gynecologic
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
Breast
1
Conditions
Lymphoma
900
Lymphoma, Non-Hodgkin
684
Leukemia, Lymphocytic, Chronic, B-Cell
665
Lymphoma, Large B-Cell, Diffuse
616
Precursor Cell Lymphoblastic Leukemia-Lymphoma
605
Lymphoma, Follicular
516
Hodgkin Disease
442
Lymphoma, Mantle-Cell
421
Leukemia
410
Lymphoma, B-Cell, Marginal Zone
289
Burkitt Lymphoma
285
Recurrence
276
Leukemia, Myeloid, Acute
276
Multiple Myeloma
250
Myelodysplastic Syndromes
237
Waldenstrom Macroglobulinemia
187
Lymphoma, B-Cell
178
Lymphoma, Large-Cell, Immunoblastic
153
Lymphoma, T-Cell, Cutaneous
143
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
127
Lymphoma, T-Cell, Peripheral
123
Mycosis Fungoides
118
Myeloproliferative Disorders
112
Lymphoma, Large-Cell, Anaplastic
107
Dendritic Cell Sarcoma, Interdigitating
103
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
102
Neoplasms
98
Lymphoma, Extranodal NK-T-Cell
96
Hematologic Neoplasms
96
Sezary Syndrome
94
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hypersensitivity
×
Lymphoid
×
Clear all
NCT04996875
2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2
Recruiting
140 enrolled